# Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

> **NCT06442475** · PHASE2 · RECRUITING · sponsor: **University of Washington** · enrollment: 20 (estimated)

## Conditions studied

- Ann Arbor Stage II Follicular Lymphoma
- Ann Arbor Stage II Marginal Zone Lymphoma
- Ann Arbor Stage III Follicular Lymphoma
- Ann Arbor Stage III Marginal Zone Lymphoma
- Ann Arbor Stage IV Follicular Lymphoma
- Ann Arbor Stage IV Marginal Zone Lymphoma
- Grade 1 Follicular Lymphoma
- Grade 2 Follicular Lymphoma
- Grade 3a Follicular Lymphoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Mosunetuzumab
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT06442475
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-29
- **Primary completion:** 2026-08-12
- **Final completion:** 2027-02-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06442475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06442475, "Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06442475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*